Jounce Therapeutics Names Jacquelyn Fahey Sandell as Chief Legal Officer and Corporate Secretary
17 September 2019 - 10:00PM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced that
Jacqui Fahey Sandell has been appointed as chief legal officer and
corporate secretary.
Jacqui brings over 20 years of experience in the
biotechnology and pharmaceutical industry, as well as in private
practice. Most recently, she served as vice president, general
counsel and corporate secretary at Vericel Corporation, where she
was responsible for all legal matters and supported the launch and
commercialization of MACI®. She has considerable experience in
healthcare and pharmaceutical law and regulation, corporate
governance, business development, commercial business transactions,
mergers and acquisitions, intellectual property, compliance, and
securities law.
“The addition of Jacqui to our team brings enormous value at
this point in our company’s lifecycle,” said Richard Murray, Ph.D.,
chief executive officer and president of Jounce Therapeutics. “She
brings a wealth of in-house biotechnology and pharmaceutical legal
experience and we believe that her expertise will be a crucial
asset as we continue to progress the company and execute on our
mission of transforming the way cancer is treated.”
Prior to her role at Vericel, Jacqui held senior legal positions
at Millennium: The Takeda Oncology Company and Genzyme Corporation.
Before joining the biotechnology and pharmaceutical industry, she
specialized in mergers and acquisitions and securities law. She
began her legal career at Shearman & Sterling in New York and
London and later practiced at Allen & Overy in Rome. Jacqui
holds a B.A. from Duke University and a J.D. from Boston University
School of Law.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical-stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long lasting
benefits to patients through a biomarker-driven approach. Through
the use of its Translational Science Platform, Jounce first focuses
on specific cell types within the human tumor microenvironment to
prioritize targets, and then identifies related biomarkers designed
to match the right immunotherapy to the right patient. Jounce is
developing two clinical-stage programs as well as advancing and
building out its broad and wholly-owned discovery pipeline of
immuno-oncology targets, including those expressed on T-regulatory
cells, macrophages and stromal cells. Jounce’s lead product
candidate, vopratelimab, is a monoclonal antibody that binds to and
activates ICOS and is currently being assessed in a Phase 2
clinical trial. JTX-4014 is a PD-1 inhibitor intended for use in
combination with future pipeline products, and Jounce has completed
enrollment in the JTX-4014 Phase 1 clinical trial. In addition,
Jounce has exclusively licensed worldwide rights to JTX-8064, a
LILRB2 receptor antagonist, to Celgene. For more information,
please visit www.jouncetx.com.
Investor Contact:Komal JoshiJounce
Therapeutics, Inc.(857) 320-2523kjoshi@jouncetx.com
Media Contact:Kathryn MorrisThe Yates
Network914-204-6412kathryn@theyatesnetwork.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2024 to May 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From May 2023 to May 2024